Skip to content

Debt-to-assets at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Amgen logo
AmgenAMGN
0.6×0.0×
Incyte logo
IncyteINCY
0.0×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
0.0×
Arcus Biosciences logo
Arcus BiosciencesRCUS
0.1×+0.1×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.0×

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s debt-to-assets?
Arcutis Biotherapeutics, Inc. (ARQT) reported debt-to-assets of 0.2× in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s debt-to-assets changed year-over-year?
Arcutis Biotherapeutics, Inc.'s debt-to-assets decreased by 22.6% year-over-year, from 0.3× to 0.2×.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s debt-to-assets has grown at a 74.0% compound annual growth rate (CAGR), from 0× to 0.3×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.